Literature DB >> 7963375

24-hour pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment.

R Fass1, C Mackel, R E Sampliner.   

Abstract

Twenty symptomatic patients without erosive esophagitis underwent 24-h esophageal pH monitoring after failing standard medical antireflux treatment. Sixty-five percent had abnormal esophageal acid exposure, and the majority of these improved on proton pump inhibitor therapy. However, 35% had a normal 24-h pH test. One patient had coronary artery disease, one had diffuse esophageal spasm, and two had a negative work-up and no improvement with omeprazole. Consequently, we suggest that patients like these have an omeprazole trial. If symptoms persist, 24-h esophageal pH monitoring can appropriately define more rational management. Patients with abnormal esophageal acid exposure will require more aggressive acid-control therapy, whereas those with normal esophageal acid exposure will need further work-up to assess the cause of their symptoms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963375     DOI: 10.1097/00004836-199409000-00003

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  10 in total

1.  Long-term experience of treating 185 patients with gastroesophageal reflux disease (GERD) by anti-reflux surgery respecting the functional-morphological restoration of the esophagus.

Authors:  R Horstmann; C Classen; S Röttgermann; M Langer; D Palmes
Journal:  Langenbecks Arch Surg       Date:  2005-11-18       Impact factor: 3.445

Review 2.  [Correct diagnosis for indication in gastroesophageal reflux disease].

Authors:  A H Hölscher; E Bollschweiler; Ch Gutschow; P Malfertheiner
Journal:  Chirurg       Date:  2005-04       Impact factor: 0.955

3.  Multichannel intraluminal impedance-pH testing is clinically useful in the management of patients with gastroesophageal reflux symptoms.

Authors:  Daniela Jodorkovsky; Jennifer C Price; Brian Kim; Sameer Dhalla; Ellen M Stein; John O Clarke
Journal:  Dig Dis Sci       Date:  2014-02-23       Impact factor: 3.199

Review 4.  Extraoesophageal manifestations of gastro-oesophageal reflux.

Authors:  J Poelmans; J Tack
Journal:  Gut       Date:  2005-10       Impact factor: 23.059

Review 5.  Diagnostic options for patients with refractory GERD.

Authors:  Fernando Fornari; Daniel Sifrim
Journal:  Curr Gastroenterol Rep       Date:  2008-06

6.  Identifying patients with gastroesophageal reflux disease: validation of a practical screening tool.

Authors:  Joshua J Ofman; Michael Shaw; Kay Sadik; Amy Grogg; Kirsten Emery; Jay Lee; Eileen Reyes; Steven Fullerton
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

7.  Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy.

Authors:  George Karamanolis; Tim Vanuytsel; Daniel Sifrim; Raf Bisschops; Joris Arts; Philip Caenepeel; Dominiek Dewulf; Jan Tack
Journal:  Dig Dis Sci       Date:  2008-03-06       Impact factor: 3.199

8.  Functional Heartburn.

Authors:  Jan Tack; Jozef Janssens
Journal:  Curr Treat Options Gastroenterol       Date:  2002-08

9.  Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded.

Authors:  Ram Dickman; Mona Boaz; Shoshanna Aizic; Zaza Beniashvili; Ronnie Fass; Yaron Niv
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

10.  A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease.

Authors:  C Keywood; M Wakefield; J Tack
Journal:  Gut       Date:  2009-05-20       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.